Dahlia Jabro

About Dahlia Jabro

Executive biopharmaceutical leader with a strong track record of advancing strategic growth, market access, and enterprise engagement across cell therapy, hematology, and rare disease markets. Experienced in navigating evolving payer landscapes, influencing access strategy, and building high-value relationships with key healthcare stakeholders to support successful commercialization and sustained patient access. I bring scientific understanding, business strategy, and executive presence to lead complex conversations across reimbursement, coverage, treatment adoption, and healthcare system priorities. Proven ability to work across cross-functional teams, which include medical affairs, sales leadership, patient services, and executive stakeholders, ultimately aligning priorities and driving measurable business impact. I support highly specialized therapies in settings where patient access, reimbursement pathways, and treatment complexity require strategic problem solving, strong collaboration, and thoughtful account leadership. I am particularly passionate about helping innovative therapies reach patients with serious unmet needs while contributing to organizations focused on scientific advancement, rare disease innovation, and long-term healthcare value. I am known for strong consultative leadership, strategic agility, and the ability to identify opportunities that strengthen both organizational goals and patient outcomes in competitive and rapidly evolving markets. My expertise in reimbursement models includes Medicare Part B, 340B, buy-and-bill, and specialty pharmacy distribution. I help health systems navigate financial and operational considerations while supporting improved patient care

Experience

1. Health Systems Associate Director (Hsad)

   SUN PHARMA

   Sep 2025 — Present · Los Angeles, CA, US

   Secure product access across multiple IDN systems by building strategic, trust-based relationships with clinical, pharmacy, administrative, and executive stakeholders • Influence formulary and treatment pathway decisions, resulting in expanded patient access and increased utilization of key oncology, immunology, and dermatology brands • Drive measurable pull-through by analyzing account-level opportunities and partnering cross-functionally with Commercial teams • Improved reimbursement confidence and site-of-care efficiency by guiding accounts through Medicare Part B, 340B and commercial coverage pathways

Education

• San Diego State University

  BA

• San Diego State University

  Master of Public Health - MPH

Skills

• Hospitals
• Pediatrics
• Pharmaceutical Industry
• Accountable Care Organizations
• Diabetes
• Product Launch
• Pharmaceutical Sales
• Health Systems
• Endocrinology
• Sales
• Hospital Sales
• Internal Medicine
• Infectious Diseases
• Osteoporosis
• Injectable
• Primary Care
• Sales Effectiveness
• Value Based Selling
• Biologics
• Ipa
• Managed Care